Mar Vista Investment Partners LLC Purchases 8,353 Shares of Stryker Corporation (NYSE:SYK)

Mar Vista Investment Partners LLC grew its position in Stryker Corporation (NYSE:SYK - Free Report) by 10.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 90,187 shares of the medical technology company's stock after buying an additional 8,353 shares during the period. Stryker accounts for approximately 2.8% of Mar Vista Investment Partners LLC's investment portfolio, making the stock its 17th largest holding. Mar Vista Investment Partners LLC's holdings in Stryker were worth $33,572,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in SYK. Brighton Jones LLC increased its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after buying an additional 609 shares during the period. Assetmark Inc. grew its stake in shares of Stryker by 28.1% during the fourth quarter. Assetmark Inc. now owns 1,298 shares of the medical technology company's stock worth $467,000 after purchasing an additional 285 shares during the period. Proficio Capital Partners LLC grew its stake in shares of Stryker by 46.2% during the fourth quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock worth $596,000 after purchasing an additional 523 shares during the period. Independent Advisor Alliance grew its stake in shares of Stryker by 19.4% during the fourth quarter. Independent Advisor Alliance now owns 8,149 shares of the medical technology company's stock worth $2,934,000 after purchasing an additional 1,325 shares during the period. Finally, Sequoia Financial Advisors LLC grew its stake in shares of Stryker by 7.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 12,074 shares of the medical technology company's stock worth $4,347,000 after purchasing an additional 838 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 1.4%

SYK traded down $5.53 on Friday, hitting $389.24. 825,133 shares of the company were exchanged, compared to its average volume of 1,354,569. Stryker Corporation has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a market cap of $148.57 billion, a PE ratio of 52.60, a PEG ratio of 2.94 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The stock's fifty day moving average is $384.79 and its 200-day moving average is $377.14.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the prior year, the company posted $2.50 earnings per share. Stryker's revenue was up 11.9% on a year-over-year basis. Equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker's dividend payout ratio is 45.41%.

Analysts Set New Price Targets

A number of brokerages recently commented on SYK. Sanford C. Bernstein set a $450.00 price objective on Stryker in a research note on Monday, May 5th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Evercore ISI boosted their target price on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Finally, Roth Mkm boosted their target price on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $428.55.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.